The Analyst Verdict: Globus Medical In The Eyes Of 13 Experts
Benzinga Insights 9 months ago
Analyst Ratings
During the last three months, 13 analysts shared their evaluations of Globus Medical (NYSE:GMED), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 6 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 2 | 1 | 0 | 0 |
| 3M Ago | 3 | 3 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $100.38, a high estimate of $115.00, and a low estimate of $79.00. Surpassing the previous average price target of $84.55, the current average has increased by 18.72%.
Investigating Analyst Ratings: An Elaborate Study
The perception of Globus Medical by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Saxon | Needham | Announces | Buy | $112.00 | - |
| Caitlin Cronin | Canaccord Genuity | Raises | Buy | $112.00 | $105.00 |
| Matt O'Brien | Piper Sandler | Raises | Overweight | $115.00 | $90.00 |
| Caitlin Cronin | Canaccord Genuity | Raises | Buy | $105.00 | $90.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $100.00 | $92.00 |
| Keith Hinton | Freedom Capital Markets | Announces | Hold | $87.00 | - |
| Drew Ranieri | Morgan Stanley | Raises | Overweight | $100.00 | $70.00 |
| Richard Newitter | Truist Securities | Raises | Buy | $105.00 | $93.00 |
| Matt Miksic | Barclays | Raises | Overweight | $114.00 | $106.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $92.00 | $88.00 |
| Vik Chopra | Wells Fargo | Raises | Overweight | $79.00 | $66.00 |
| Craig Bijou | B of A Securities | Raises | Buy | $91.00 | $65.00 |
| Richard Newitter | Truist Securities | Raises | Buy | $93.00 | $65.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Globus Medical. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Globus Medical compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Globus Medical's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Globus Medical's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Globus Medical analyst ratings.
Delving into Globus Medical's Background
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
Breaking Down Globus Medical's Financial Performance
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Globus Medical displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 22.91%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Globus Medical's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 15.47%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Globus Medical's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.74%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Globus Medical's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.37%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.03, Globus Medical adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Significance of Analyst Ratings Explained
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.